Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 851 to 900 of 1247

TitleReference numberPublishedLast updated
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Developmental follow-up of children and young people born pretermNG72
Cabozantinib for previously treated advanced renal cell carcinomaTA463
Baricitinib for moderate to severe rheumatoid arthritisTA466
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutritionCG32
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Roflumilast for treating chronic obstructive pulmonary diseaseTA461
Nivolumab for treating relapsed or refractory classical Hodgkin lymphomaTA462
Parkinson's disease in adultsNG71
Constipation in children and young people: diagnosis and managementCG99
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Ustekinumab for moderately to severely active Crohn's disease after previous treatmentTA456
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)TA453
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA454
Air pollution: outdoor air quality and healthNG70
Eliglustat for treating type 1 Gaucher diseaseHST5
Etelcalcetide for treating secondary hyperparathyroidismTA448
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive diseaseTA449
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaTA450
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaTA451
Spondyloarthritis in over 16s: diagnosis and managementNG65
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDsTA445
Idiopathic pulmonary fibrosis in adults: diagnosis and managementCG163
Intravenous fluid therapy in adults in hospitalCG174
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Obeticholic acid for treating primary biliary cholangitisTA443
Antisocial behaviour and conduct disorders in children and young people: recognition and managementCG158
Alcohol-use disorders: diagnosis and management of physical complicationsCG100
Sexually transmitted infections: condom distribution schemesNG68
Irritable bowel syndrome in adults: diagnosis and managementCG61
Managing medicines for adults receiving social care in the communityNG67
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Patient group directionsMPG2
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Mental health of adults in contact with the criminal justice systemNG66
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for treating moderate to severe plaque psoriasisTA180
Migalastat for treating Fabry diseaseHST4
Drug misuse prevention: targeted interventionsNG64
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Healthcare-associated infections: prevention and control in primary and community careCG139
Osteoporosis: assessing the risk of fragility fractureCG146

Results per page

  1. 10
  2. 25
  3. 50
  4. All